Cholinesterase inhibitors and the risk of pulmonary disorders in hospitalized dementia patients

Canadian Journal of Clinical Pharmacology

Volumn 17, Issue 3, 2010, Pages

  Helou, Raphael ^a   Rhalimi, Mounir ^b  

^a Juel Hospital   (France)

^b Bertinot Juel Hospital   (France)

Author keywords

Alzheimer; Cholinesterase inhibitor; Dementia; Pulmonary disorders

Indexed keywords

DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

ACUTE RESPIRATORY FAILURE; AGED; ALZHEIMER DISEASE; ARTICLE; ASTHMA; BODY WEIGHT; BRONCHITIS; COUGHING; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL METHOD; OUTCOME ASSESSMENT; PRESCRIPTION; PROSPECTIVE STUDY; RISK;

EID: 78951488627     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Bailar JC 3rd, Louis TA, Lavori PW, Polansky M. A classification for biomedical research reports. N Engl J Med 1984 Dec 6;311(23):1482-7.
2. Sener S, Ozsarac M. Case of the month: rivastigmine (Exelon) toxicity with evidence of respiratory depression. Emerg Med J 2006 Jan;23(1):82-5.
3. Taylor AM, Hoehns JD, Anderson DM, Tobert DG. Fatal aspiration pneumonia during transition from donepezil to rivastigmine. Ann Pharmacother 2002 Oct;36(10):1550-3.
4. Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001 Dec;49(12):1590-9.
5. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001 Aug 14;57(3):489-95.
6. Lyketsos CG, Reichman WE, Kershaw P, Zhu Y. Long-term outcomes of galantamine treatment in patients with Alzheimer disease. Am J Geriatr Psychiatry 2004 Sep-Oct;12(5):473-82.
7. Kurz AF, Erkinjuntti T, Small GW, Lilienfeld S, Damaraju CR. Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease. Eur J Neurol 2003 Nov;10(6):633-40.
8. Rockwood K, Dai D, Mitnitski A. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months. Int J Geriatr Psychiatry 2008 Feb;23(2):207-14.
9. Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol 2004 Feb;61(2):252-6.
10. Pirttilä T, Wilcock G, Truyen L, Damaraju CV. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. Eur J Neurol 2004 Nov;11(11):734-41.
11. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998 May 11;158(9):1021-31.
12. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998 Jan;50(1):136-45.
13. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001 Aug 14;57(3):481-8.
14. Fuschillo C, Ascoli E, Franzese G, et al. Alzheimer's disease and acetylcholinesterase inhibitor agents: a two-year longitudinal study. Arch Gerontol Geriatr Suppl 2004;(9):187-94.
15. Minthon L, Wallin AK, Eriksson S, Wattmo C, Andreasen N. Long-term rivastigmine treatment in a routine clinical setting. Acta Neurol Scand 2009 Mar;119(3):180-5. Epub 2008 Aug 26.
16. Farlow MR, Lilly ML; ENA713 B352 Study Group. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years. BMC Geriatr 2005 Jan 19;5:3.
17. Aguglia E, Onor ML, Saina M, Maso E. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. Curr Med Res Opin 2004 Nov;20(11):1747-52.
18. Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005 Aug;21(8):1317-27.
19. Winblad B, Wimo A, Engedal K, et al. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord 2006;21(5-6):353-363. Epub February 27, 2006.
20. Grossberg G, Irwin P, Satlin A, Mesenbrink P, Spiegel R. Rivastigmine in Alzheimer disease: efficacy over two years. Am J Geriatr Psychiatry 2004 Jul-Aug;12(4):420-31.
21. Homma A, Imai Y, Tago H, et al. Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan. Dement Geriatr Cogn Disord 2009;27(3):232-9. Epub 2009 Feb 25.
22. Griffith P, Lichtenberg P, Goldman R, Payne-Parrish J. Safety and efficacy of donepezil in African Americans with mild-to-moderate Alzheimer's disease. J Natl Med Assoc 2006 Oct;98(10):1590-7.
23. Mossello E, Tonon E, Caleri V, et al. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a real world study. Archives of Gerontology and Geriatrics 2004(9):297-307.
24. Gill SS, Bronskill SE, Mamdani M, et al. Representation of patients with dementia in clinical trials of donepezil. Can J Clin Pharmacol 2004 Fall;11(2):e274-85. Epub Dec 15, 2004.
25. Wilkinson D, Murray J. Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2001 Sep;16(9):852-7.
26. Raschetti R, Maggini M, Sorrentino GC, Martini N, Caffari B, Vanacore N. A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease. Eur J Clin Pharmacol 2005 Jul;61(5-6):361-8. Epub May 24, 2005.
27. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomized double-blind trial. Lancet 2004 Jun 26;363(9427):2105-15.
28. Doody RS, GeldmChEIr DS, Gordon B, Perdomo CA, Pratt RD. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001 Mar;58(3):427-33.